Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02722668 · OUTCOME

Probability of Acute Graft Versus Host Disease (GVHD)

UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep · Source last updated 2025-07-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percent of participants
Interval / dispersion
95% Confidence Interval
Time frame
Day 100

What was measured

Simple proportions will be used to estimate the probability of grade II-IV actue GVHD.

Groups in this outcome

No Anti-thymocyte Globulin (ATG)

Hematologic malignancy patients who have received a previous autologous transplant or ≥ 2 cycles of multi-agent chemotherapy within the 3 months previous to umbilical cord blood transplantation.

Anti-thymocyte Globulin (ATG)

Hematologic malignancy patients who have not been treated with prior autologous transplant or ≤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplantation, should receive Anti-thymocyte Globulin (ATG) as part of their conditioning regimen.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
No Anti-thymocyte Globulin (ATG)5
Anti-thymocyte Globulin (ATG)10

Reported measurements

Source class 1
Values in Percent of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
No Anti-thymocyte Globulin (ATG)0Not reported0100Not reported
Anti-thymocyte Globulin (ATG)30Not reported357Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0
        upper Limit
        100
        value
        0
      2. group Id
        OG001
        lower Limit
        3
        upper Limit
        57
        value
        30
denoms
  1. counts
    1. group Id
      OG000
      value
      5
    2. group Id
      OG001
      value
      10
    units
    Participants
description
Simple proportions will be used to estimate the probability of grade II-IV actue GVHD.
dispersion Type
95% Confidence Interval
groups
  1. description
    Hematologic malignancy patients who have received a previous autologous transplant or ≥ 2 cycles of multi-agent chemotherapy within the 3 months previous to umbilical cord blood transplantation.
    id
    OG000
    title
    No Anti-thymocyte Globulin (ATG)
  2. description
    Hematologic malignancy patients who have not been treated with prior autologous transplant or ≤ 1 cycle of chemotherapy in the 3 months previous to umbilical cord blood transplantation, should receive Anti-thymocyte Globulin (ATG) as part of their conditioning regimen.
    id
    OG001
    title
    Anti-thymocyte Globulin (ATG)
param Type
NUMBER
reporting Status
POSTED
time Frame
Day 100
title
Probability of Acute Graft Versus Host Disease (GVHD)
type
PRIMARY
unit Of Measure
Percent of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice